What does BPC-157 do?
BPC-157 is studied for its potential role in supporting tissue repair, blood vessel growth, and digestive tract protection, largely based on animal and laboratory research.
Is BPC-157 FDA-approved?
No. BPC-157 does not have FDA approval for any use, and its regulatory status for pharmacy compounding has changed over time as the FDA continues to review it.
How long before I may notice changes?
Responses vary considerably, and because human research is limited, there is no well-established timeline for expected results.
Is it an injection?
BPC-157 is typically administered as a subcutaneous injection, though other forms may be discussed with your provider depending on current availability.
Can it be combined with other peptides?
Some providers combine BPC-157 with other recovery-focused peptides, such as in the Wolverine Blend. This should always be discussed with your provider first.
Can it be combined with GLP-1 medications?
This should be discussed individually with your provider, who can evaluate your full treatment plan.
Will I need lab work?
Your provider may recommend baseline evaluation as part of a thorough, individualized approach to this peptide.
Who should avoid this peptide?
Patients with certain active health conditions may not be appropriate candidates. A full medical evaluation will help determine this, especially given the limited human safety data currently available.
How long do patients typically remain on therapy?
Treatment length varies by individual goals, and given the evolving evidence base, your provider will help determine a reasonable, individualized plan.
Is a consultation required?
Yes. A telehealth consultation with a licensed medical provider is required before starting BPC-157 or any peptide therapy at SevenHealth.